Novel and emerging drugs for systemic lupus erythematosus: Mechanism of action and therapeutic activity

Current Medicinal Chemistry

Volumn 19, Issue 3, 2012, Pages 438-453

  Robak, E ^a   Robak, T ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Abatacept; Abetimus; Bindarit; Cyclosporine A; Cytokines; Edratide; Interferon; Monoclonal antibodies; MTOR inhibitors; Prasterone; Sirolimus; SLE; Statins; Tacrolimus

Indexed keywords

ABATACEPT; ABETIMUS; ATACICEPT; ATORVASTATIN; BELIMUMAB; BINDARIT; CYCLOSPORIN A; ECULIZUMAB; EDRATIDE; ETANERCEPT; FORIGERIMOD; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AGS 009; MONOCLONAL ANTIBODY AMG 811; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PLACEBO; PRASTERONE; RAPAMYCIN; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; SIMVASTATIN; SIRUKUMAB; TACROLIMUS; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; NONHUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84857706811     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803414312     Document Type: Review

References (181)

1. Rahman, A.; Isenberg, D.A. Systemic lupus erythematosus. N. Engl. J. Med., 2008,358,929-939. (Pubitemid 351397092)
2. Ruiz-Irastorza, G.; Khamashta, M.A.; Castelino, G., Hughes G.R. Systemic lupus erythematosus. Lancet, 2001, 357, 1027-1032. (Pubitemid 32285401)
3. Fu, S.M.; Deshmukh, U.S.; Gaskin, F. Pathogenesis of systemic lupus erythematosus revisited 2011: End organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun. 2011, 37,104-112.
4. Diamond, B.; Bloom, O.; Al Abed, Y.; Kowal, C.; Huerta, P.T.; Volpe, B.T. Moving towards a cure: Blocking pathogenic an antibodies in systemic lupus erythematosus. J. Intern. Med., 2011, 269,36-44.
5. Rönnblom, L. Potential role of IFN alpha in adult lupus. Arthritis Res Ther., 2010,12(Suppl 1),S3.
6. Mills, J.A. Systemic lupus erythematosus. N. Engl. J. Med., 1994, 330, 1871-1879.
7. Wozniacka, A.; Lesiak, A.; Boncela, J.; Smolarczyk, K.; McCauliffe, D.P.; Sysa-Jedrzejowska A. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br. J. Dermatol. 2008,159, 1124-1130.
8. Schröder ,J.O.; Zeuner, R.A. Biologics as treatment for systemic lupus: Great efforts, sobering results, new challenges. Curr. Drug. Discov. Technol., 2009;6:252-255.
9. Yildirim-Toruner, C.; Diamond, B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol., 2011,127,303-12.
10. Gayed, M.; Gordon, C. Novel treatments for systemic lupus erythematosus. Curr. Opin. Investig. Drugs., 2010,11,1256-1264.
11. Mok, M.Y. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int. J. Rheum. Dis., 2010,13,3-11.
12. Yildirim-Torune,r C.; Diamond, B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J. Allergy Clin. Immunol., 2011,127,303-312.
13. Griffiths, B.; Emery, P. The treatment of lupus with cyclosporin A. Lupus, 2001, 10,165-170. (Pubitemid 32410072)
14. Musson, R.E.; Smit, N.P. Regulatory mechanisms of calcineurin phosphatase activity. Curr. Med. Chem., 2011,18,301-315.
15. Fu, L.W; Yang, L.Y.; Chen, W.P.; Lin, C.Y. Clinical efficacy of cyclosporin A neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br. J. Rheumatol., 1998,37,217-221.
16. Caccavo, D.; Lagana, B.; Mitterhofer, A.P.; Ferri, G.M.; Afeltra, A.; Amoroso, A.; Bonomo, L. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum., 1997, 40, 27-35. (Pubitemid 27044033)
17. Sakano, T.; Ohta, T.; Kinoshita, Y.; Fjiwara, M.; Wakai, M. Treatment of steroid resistant systemic lupus erythematosus with extremely low dose of cyclosporine A. Pediatr. Int., 2004, 46, 468-470. (Pubitemid 39119164)
18. Wozniacka, A.; Salamon, M; Lesiak, A.; McCauliffe, D.P.; Sysa- Jedrzejowska A. The dynamism of cutaneous lupus erythematosus: Mild discoid lupus erythematosus evolving into SLE with SCLE and treatmentresistant lupus panniculitis. Clin Rheumatol. 2007, 26,1176-1179. (Pubitemid 46863973)
19. Sugiyama, M.; Ogasawara, H.; Kaneko, H.; Hishikawa, T.; Sekigawa, I.; Iida, N.; Hashimoto, H.; Hirose, S. Effect of extremely low dose cyclosporine treatment on the thrombocytopenia in systemic lupus erythematosus. Lupus, 1998, 7, 53-56. (Pubitemid 28052664)
20. Quartuccio, L.; Sacco, S.; Franzolini, N.; Perin, A.; Ferraccioli, G.; De Vita, S. Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus, 2006;15:76-79. (Pubitemid 43345331)
21. Radhakrishnan, J.; Kunis, C.; D'Agat,i V.; Appel, G.B. Cyclosporine treatment of lupus membranous nephropathy. Clin. Nephrol., 1994, 42,147-154. (Pubitemid 24287748)
22. Manger, K.; Kalden ,J.R.; Manger, B. Cyclosporin A in the treatment of systemic lupus erythematosus: Results of an open clinical study. Br. J. Rheumatol., 1996, 35, 669-675.
23. Ogawa, H.; Kameda, H.; Amano, K.; Takeuchi, T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus, 2010, 19,162-169.
24. Griffiths, B.; Emery, P.; Ryan, V.; Isenberg, D.; Akil, M.; Thompson, R.; Maddison, P.; Griffiths, I.D.; Lorenzi, A.; Miles, S.; Situnayake, D.; The, L.S.; Plant, M.; Hallengren, C.; Nived, O.; Sturfelt, G.; Chakravarty, K.; Tait, T.; Gordon, C. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology, 2010, 49,723-732.
25. Kuiper-Geertsma, D.G.; Derksen, R.H. Newer drugs for the treatment of lupus nephritis. Drugs, 2003, 63, 167-180. (Pubitemid 36143343)
26. Yoon, K.H. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: A review. J. Biomed. Biotechnol., 2010,686480.
27. Tanaka, H.; Oki, E.; Tsugawa, K.; Nonaka, K.; Suzuki, K.; Ito, E. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: An open-label pilot study. Lupus, 2007,16,896-900 . (Pubitemid 350157276)
28. Kuiper-Geertsma, D.G.; Derksen, R.H. Newer drugs for the treatment of lupus nephritis. Drugs, 2003, 63, 167-180. (Pubitemid 36143343)
29. Heidt, S.; Roelen, D.L.; Eijsink, C.; Eikmans, M.; van Kooten, C.; Claas, F.H.; Mulder, A. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. J. Transl. Immunol., 2009, 159, 199-207.
30. Takabayashi, K.; Koike, T.; Kurasawa, K.; Matsumura R, Sato, T.; Tomioka, H.; Ito, I.; Yoshiki, T.; Yoshida, S. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus, Clin. Immunol. Immunopathol., 1989, 51,110-117. (Pubitemid 19096341)
31. Entani, C.; Izumino, Y.; Iida, H.; Fujita, M.; Asaka, M.; Takata, M.; Sasayama, S. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-pr/lpr mice. Nephron, 1993,64, 471-475. (Pubitemid 23202862)
32. Duddridge, M.; Powel,l R.J. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann. Rheum. Dis., 1997, 56, 690-692. (Pubitemid 28007929)
33. Alsuwaida, A. Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. Mod Rheumatol., 2011, 21,73-75.
34. Politt, D.; Heintz, B.; Floege, J.; Mertens, P.R. Tacrolimus (FK-506) based immunosuppression in severe systemic lupus erythematosus. Clin. Nephrol., 2004; 62: 49-53. (Pubitemid 38986903)
35. Morimoto S, Watanabe T, Lee S, Amano H, Kanamaru Y, Ohsawa I, Tomino Y, Takasaki Y. Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus. Mod Rheumatol. 2010;20:291-294.
36. Mok, C.C.;Tong, K.H.; To, Ch.; Siu, Y.P. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open- labeled pilot study. Kidney Int., 2005, 68, 813-817. (Pubitemid 43323138)
37. Asamiya Y, Uchida K, Otsubo S, Takei T, Nitta K. ., Clinical assessment of tacrolimus therapy in lupus nephritis: One-year follow-up study in a single center, Nephron Clin. Pract., 2009, 113, 330-336.
38. Nobuyuki, M.; Shinichi, K.; Hiroshi, H. Efficacy and safety of tacrolimus for lupus nephritis: A placebo-controlled double-blind multicenter study,Modern Rheumatology, 2009, 19, 606-615.
39. Szeto, C.C.; Kwan, B.C.; Lai, F.M.; Tam, L.S.; Li, E.K.; Chow, K.M.; Gang, W.; Li, P.K. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology, 2008, 47,1678-1681.
40. Alsuwaida, A.; Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. Mod. Rheumatol. 2011, 21,73-75.
41. Suzuki, K.; Kameda, H.; Amano, K.; Nagasawa, H.; Takei, H.; Nishi, E.; Okuyama, A.; Tsuzaka, K.; Takeuchi, T. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol. Int., 2011,31,757-63.
42. Kusunoki, Y.; Tanaka, N.; Kaneko, K.; Yamamoto, T.; Endo, H.; Kawai, S. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: A preliminary retrospective study. Mod. Rheumatol., 2009,19, 616-21.
43. Kanekura, T.; Yoshii, N.; Terasaki, K.; Miyoshi, H.; Kanzaki, T. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br. J. Dermatol., 2003, 148, 353-356. (Pubitemid 36278982)
44. Heymann, W.R. Mycophenolate mofetil. J. Am. Acad. Dermatol., 2005, 53, 1045-1046. (Pubitemid 41677330)
45. Gaubitz, M.; Schorat, A.; Schotte, H.; Kern, P.; Domschke, W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: An open pilot trial. Lupus, 1999, 8, 731-736.
46. Kingdon, E.J.; McLean, A.G.; Psimenou, E.; Davenport, A.; Powis, S.H.; Sweny, P.; Burns, A. The safety and efficacy of MMF in lupus nephritis: A pilot study. Lupus, 2001, 10, 606-611. (Pubitemid 32959274)
47. Karim, M.Y.; Alba, P.; Cuadrado, M.J.; Abbs, I.C.; D'Cruz, D.P.; Khamashta, M.A, Hughes, G.R. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatol., 2002, 41, 876-882.
48. Briggs, W.A.; Choi, M.J.; Scheel, P.J. Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am. J. Kidney Dis., 1998, 31, 213-217.
49. Glicklich, D.; Acharya, A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis., 1998,32, 318-322.
50. Dooley, M.A., Cosio, F.G., Nachman, P.H.; Falkenhain, M.E.; Hogan, S.L.; Falk, R.J.; Hebert, L.A. Mycophenolate mofetil therapy in lupus nephritis clinical observations. J. Am. Soc. Nephrol., 1999, 10, 833-839. (Pubitemid 29149534)
51. Mino, Y.; Naito, T.; Shimoyama, K.; Ogawa, N.; Kawakami, J. Pharmacokinetic variability of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in remission maintenance phase. Biol. Pharm. Bull. 2011, 34,755-759.
52. Ginzler, E.M.; Dooley, M.A.; Aranow, C.; Kim, M.Y.; Buyon, J.; Merrill, J.T.; Petri, M.; Gilkeson, G.S.; Wallace, D.J.; Weisman, M.H.; Appel, G.B. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med., 2005, 353, 2219-222.
53. Contreras, G.; Pardo, V.; Leclercq, B.; Lenz, O.; Tozman, E.; O'Nan, P.; Roth, D. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med., 2004, 350, 971-980. (Pubitemid 38269274)
54. Goyal, S.; Nousari, H.C. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J. Am. Acad. Dermatol., 2001, 45, 142-144. (Pubitemid 32655712)
55. Hanjani, N.M.; Nousari, C.H. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch. Dermatol., 2002, 138, 1616-1618. (Pubitemid 35453486)
56. Schanz, S.; Ulmer, A.; Rassner, G.; Fierlbeck, G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br. J. Dermatol., 2002, 147, 174-178. (Pubitemid 34779458)
57. Vasoo, S.; Thumboo, J.; Fong, K.Y. Refractory immune thrombocytopenia in systemic lupus erythematosus: Response to mycophenolate mofetil. Lupus, 2003, 12, 630-632. (Pubitemid 37021800)
58. Alba, P.; Karim, M.Y.; Hunt, B.J. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus, 2003, 12, 633-635. (Pubitemid 37021801)
59. Samad, A.S.; Lindsley, C.B. Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. South. Med. J., 2003,96, 705-707. (Pubitemid 38292569)
60. Riskalla, M.M.; Somers, E.C.; Fatica, R.A.; McCune, W.J. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J. Rheumatol., 2003, 30, 1508-1512. (Pubitemid 36835447)
61. Heymann, W.R. Mycophenolate mofetil. J. Am. Acad. Dermatol. 2005, 53, 1045-1046. (Pubitemid 41677330)
62. Laplante, M.; Sabatini, D.M. mTOR signaling at a glance. J. Cell Sci. 2009,122,3589-94.
63. Fernandez, D.; Perl, A. mTOR signaling: A central pathway to pathogenesis in systemic lupus erythematosus? Discov. Med., 2010,9,173-8.
64. Costa, L.J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev., 2007,33,78-84. (Pubitemid 46132007)
65. Smolewski, P. Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opin. Investig. Drugs, 2006,15, 1201-1227. (Pubitemid 44608260)
66. Janus, A.; Robak, T.; Smolewski, P. The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumour therapy. Cell. Mol. Biol. Lett., 2005, 10, 479-498. (Pubitemid 41564520)
67. Rowinsky, E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol., 2004,16,564-75. (Pubitemid 39482975)
68. Smolewski, P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs, 2006, 17, 487-94. (Pubitemid 44309964)
69. Araki, K, Turner, A.P.; Shaffer, V.O.; Gangappa, S.; Keller, S.A.; Bachmann, M.F.; Larsen, C.P.; Ahmed, R. mTOR regulates memory CD8 Tcell differentiation. Nature, 2009 ,460,108-12.
70. Fernandez, D.; Perl, A. mTOR signaling: A central pathway to pathogenesis in systemic lupus erythematosus? Discov. Med., 2010, 9,173-8.
71. Warner, L.M.; Adams, L.M.; Sehgal, S.N. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum., 1994,37,289-297. (Pubitemid 24065505)
72. Lorenz, H.M. Abetimus (La Jolla pharmaceuticals). Curr. Opin. Investig. Drugs, 2002, 3, 234-239.
73. Jones, D.S.; Hachmann, J.P.; Osgood, S.A.; Hayag, M.S.; Barstad, P.A.; Iverson, G.M.; Coutts, S.M. Conjugates of double-stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: A model for treating systemic lupus erythematosus. Bioconjug Chem., 1994,5,390-399. (Pubitemid 2144394)
74. Cardiel, M.H.; Tumlin, J.A.; Furie, R.A.; Wallace, D.J.; Joh, T.; Linnik, M.D.; LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial. Arthritis Rheum., 2008,58, 2470-2480.
75. Linnik, M.D.; O'Rourke, A.M.; Crowther, M.A. Pharmacokinetics of highdose abetimus sodium in normal subjects with specific assessment of effect on coagulation. J. Clin. Pharmacol., 2008,48, 909-918. (Pubitemid 352009490)
76. Mikael, N.; Boguniewicz, M.; Manakata, Y.; Sasaki, T.; Borel, H.; Borel, Y. Conjugates or dsDNA linked to human gammaglobulin inhibit anti-dsDNA antibodies in vitro. Lupus, 1994, 3,173-179. (Pubitemid 24229885)
77. Coutts, S.M.; Plunkett, M.L.; Iverson, G.M.; Barstad, P.A.; Berner, C.M. Pharmacological intervention in antibody mediated disease. Lupus, 1996,5,158-159. (Pubitemid 26135163)
78. Lorenz, H.M., Abetimus (La Jolla Pharmaceuticals). Curr. Opin. Investig. Drugs, 2002, 3, 234-239.
79. Horowitz, D.M.; Furie, R.A. Abetimus sodium: A medication for the prevention of lupus nephritis flares. Expert. Opin. Pharmacother., 2009,10,1501-1507.
80. Cardiel, M.H. Abetimus sodium: A new therapy for delaying the time to, and reducing the incidence of renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. Expert. Opin. Investig. Drugs, 2005,14, 77-88.
81. Strand, V.; Aranow, C.; Cardie,l M.H.; Alarcón-Segovia, D.; Furie, R.; Sherrer, Y.; Tumlin, J.; Wallace, D.J.; Crawford, B.; LJP 394 Investigator Consortium. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus, 2003,12,677-686. (Pubitemid 37173664)
82. Cardie,l M.H.; Tumlin, J.A.; Furie, R.A.; Wallace, D.J.; Joh, T.; Linnik, M.D. LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial. Arthritis Rheum., 2008,58,2470-2480.
83. Abetimus: Abetimus sodium, LJP 394. BioDrugs., 2003,17,212-215.
84. Hornsby, P.J. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann. N. Y. Acad. Sci., 1995, 774, 29-46. (Pubitemid 26140358)
85. Lahita, R.G.; Bradlow, H.L.; Ginzler, E.; Pang, S.; New, M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum., 1987, 30, 241-248. (Pubitemid 17098574)
86. Mease, P.J.; Ginzler, E.M.; Gluck, O.S.; Schiff, M.; Goldman, A.; Greenwald, M.; Cohen, S.; Egan, R.; Quarles, B.J.; Schwartz, K.E. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. J. Rheumatol., 2005,32, 616-621. (Pubitemid 40524691)
87. Kocis, P.; Prasterone. Am J Health Syst Pharm., 2006,63, 2201-2210.
88. Van Vollenhoven, R.F.; Engleman, E.G.; McGuire, J.L. Dehydroepiandrosterone in systemic lupus erythematosus: Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum., 1995,38,1826-1831. (Pubitemid 26010284)
89. Petri, M.A.; Mease, P.J.; Merrill, J.T.; Lahita, R.G.; Iannini, M.J.; Yocum, D.E.; Ginzler, E.M.; Katz, R.S.; Gluck, O.S.; Genovese, M.C.; Van Vollenhoven, R.; Kalunian, K.C.; Manzi, S.; Greenwald, M.W.; Buyon, J.P., Olsen, N.J.; Schiff, M.H.; Kavanaugh, A.F.; Caldwell, J.R.; Ramsey- Goldman, R.; St Clair, E.W.; Goldman, A.L.; Egan, R.M.; Polisson, R.P.; Moder, K.G.; Rothfield, N.F.; Spencer, R.T.; Hobbs, K.; Fessler, B.J.; Calabrese, L.H.; Moreland, L.W.; Cohen, S.B.; Quarles, B.J.; Strand, V.; Gurwith, M.; Schwartz, K.E. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum., 2004,50,2858-2868.
90. Sironi, M.; Guglielmotti, A.; Polentarutti, N.; Fioretti, F.; Milanese, C.; Romano, M.; Vigini, C.; Coletta, I.; Sozzani, S.; Bernasconi, S.; Vecchi, A.; Pinza, M.; Mantovan,i A. A small synthetic molecule capable of preferentially inhibiting the production of the CC chemokine monocyte chemotactic protein-1. Eur. Cytokine Netw., 1999,10,437-442.
91. Mirolo, M.; Fabbri, M.; Sironi, M.; Vecchi, A.; Guglielmotti, A.; Mangano, G.; Biondi, G.; Locati, M.; Mantovani, A. Impact of the anti-inflammatory agent bindarit on the chemokinome: Selective inhibition of the monocyte chemotactic proteins. Eur. Cytokine Netw., 2008,19,119-122.
92. Guglielmotti, A.; D'Onofrio, E.; Coletta, I.; Aquilini, L.; Milanese, C.; Pinza, M.; Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-alpha production. Inflamm Res, 2002,51,252-258. (Pubitemid 34526441)
93. Cioli, V.; Ciarniello, M.G.; Guglielmotti, A.; Luparini, M.R.; Durando, L.; Martinelli, B.; Catanese, B.; Fava, L.; Silvestrini, B. A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats. J. Rheumatol.,1992,19,1735-1742.
94. Guglielmotti, A.; Silvestrini, B.; Saso, L.; Zwain, I.; Cheng, C.Y. Chronic inflammatory response in the rat can be blocked by bindarit. Biochem. Mol. Biol. Int .,1993,29,747-756. (Pubitemid 23164767)
95. Guglielmotti, A.; Aquilini, L.; D'Onofrio, E.; Rosignoli, M.T.; Milanese, C.; Pinza, M. Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice. Clin. Exp. Rheumatol., 1998,16,149-154. (Pubitemid 28241568)
96. Sandborg, C.; Ardoin, S.P.; Schanberg, L. Therapy Insight: Cardiovascular disease in pediatric systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol., 2008 ,4,258-265. (Pubitemid 351638683)
97. Rao, S.; Porter, D.C.; Chen, X.; Herliczek, T.; Lowe, M.; Keyomarsi, K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA., 1999,96,7797-7802. (Pubitemid 29328361)
98. Demierre, M.F.; Higgins, P.D.; Gruber, S.B.; Hawk, E.; Lippman, S.M. Statins and cancer prevention. Nat. Rev. Cancer., 2005,5,930-942. (Pubitemid 41766782)
99. Rosenson, R.S.; Tangney, C.C. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA,1998, 279,1643-1650. (Pubitemid 28248591)
100. Bielinska, A.; Gluszko, P. Statins-are they potentially useful in rheumatology? Pol. Arch. Med. Wewn., 2007,117, 420-425. (Pubitemid 350190348)
101. Lawman, S.; Mauri, C.; Jury, E.C.; Cook, H.T.; Ehrenstein, M.R. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J. Immunol, 2004,173,7641-7646. (Pubitemid 39628206)
102. Graham, K.L.; Lee, L.Y.; Higgins, J.P.; Steinman, L.; Utz, P.J.; Ho, P.P. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum., 2008, 58,2098-2104. (Pubitemid 351988101)
103. Jury, E. C.; Kabouridis, P.S.; Flores-Borja, F.; Mageed, R.A.; Isenberg, D.A. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest.,2004,113,1176-1187. (Pubitemid 38544103)
104. Abud-Mendoza, C.; de la Fuente, H.; Cuevas-Orta, E.; Baranda, L.; Cruz- Rizo, J.; González-Amaro, R.Therapy with statins in patients with refractory rheumatic diseases: A preliminary study. Lupus, 2003,12,607-611. (Pubitemid 37021796)
105. Ferreira, G.A.; Navarro, T.P.; Telles, R.W., Andrade, L.E.; Sato, E. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An 8 weeks controlled trial. Rheumatology (Oxford)., 2007,46, 1560-1565. (Pubitemid 47500570)
106. Jury, E.C.; Isenberg, D.A.; Mauri, C.; Ehrenstein, M.R. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J. Immunol., 2006, 177,7416-7422. (Pubitemid 44715112)
107. Costenbader, K.H.; Liang, M.H.; Chibnik, L.B.; Aizer, J.; Kwon, H.; Gall, V.; Karlson, E.W. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol. Int., 2007,27,1071-1077. (Pubitemid 47246586)
108. Waisman, A.; Shoenfeld, Y.; Blank, M.; Ruiz, P.J.; Mozes, E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 segment. Int. Immunol., 1995;7,689-696.
109. Sharabi, A.; Luger, D.; Ben-David, H.; Dayan, M.; Zinger, H.; Mozes, E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J. Immunol., 2007,179,4979-4987.
110. Ben-David, H.; Sharabi, A.; Parameswaran, R.; Zinger, H.; Mozes, E. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupusafflicted mice by inhibition of interleukin-7, leading to apoptosis. Immunology, 2009,128,245-252.
111. Elmann, A.; Sharabi, A.; Dayan, M.; Zinger, H.; Ophir, R.; Mozes, E. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum., 2007, 56, 2371-2381. (Pubitemid 47173585)
112. Sthoeger, Z.M.; Sharabi, A.; Molad, Y.; Asher, I.; Zinger, H.; Dayan, M.; Mozes, E. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): Immunomodulation of gene expression. J. Autoimmun., 2009,33,77-82.
113. Muller, S. Novel strategy in lupus therapy: From the peptide P140 to Lupuzor. Ann Pharm Fr., 2011, 69,151-154.
114. Monneaux, F.; Lozano, J.M.; Patarroyo, M.E.; Briand, J.P.; Muller, S. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur J Immunol., 2003,33,287-296. (Pubitemid 36267592)
115. Dieker, J.; Cisterna, B.; Monneaux, F.; Decossas, M.; van der Vlag, J.; Biggiogera, M.; Muller, S. Apoptosis-linked changes in the phosphorylation status and subcellular localization of the spliceosomal autoantigen U1-70K. Cell Death Differ, 2008,15,793-804. (Pubitemid 351405084)
116. Page, N.; Schall, N.; Strub, J.M.; Quinternet, M.; Chaloin, O.; Décossas, M.; Cung, M.T.; Van Dorsselaer, A.; Briand, J.P.; Muller, S.The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells. PLoS ONE 2009,4,e5273.
117. Page, N.; Gros, F.; Schall, N.; Décossas, M.; Bagnard, D.; Briand, J.P.; Muller, S. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann Rheum Dis., 2011, 70,837-843.
118. Page, N.; Gros, F.; Schall, N.; Briand, J.P.; Muller, S. A therapeutic peptide in lupus alters autophagic processes and stability of MHCII molecules in MRL/lpr B cells. Autophagy, 2011, 7, 539-540.
119. Monneaux, F.; Lozano, J.M.; Patarroyo, M.E.; Briand, J.P.; Muller, S. T cell recognition and therapeutic effects of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr lupus mice. Eur J Immunol, 2003, 33, 287-296. (Pubitemid 36267592)
120. Muller, S.; Monneaux, F.; Schall, N.; Rashkov, R.K.; Oparanov, B.A.; Wiesel, P.; Geiger, J.M.; Zimmer, R. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial. Arthritis Rheum., 2008,58, 3873-3883.
121. St Clair, E.W. Novel targeted therapies for autoimmunity. Curr. Opin. Immunol., 2009, 21, 648-657.
122. Goeb, V.; Buch, M.H.; Vital, E.M.; Emery, P. Costimulation blockade in rheumatic diseases: Where we are? Curr. Opin. Rheumatol., 2009, 21, 244-250.
123. Lateef, A.; Petri, M. Biologics in the treatment of systemic lupus erythematosus. Curr. Opin. Rheumatol., 2010, 22, 504-509.
124. Yamada, A.; Salama, A.D.; Sayegh, M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol., 2002,13,559-575. (Pubitemid 34106301)
125. Bruce, S.P.; Boyce, E.G. Update on abatacept: A selective costimulation modulator for rheumatoid arthritis. Ann Pharmacother. 2007, 41,1153-1162. (Pubitemid 47122552)
126. Korhonen, R.; Moilanen, E. Abatacept, a novel CD80/86-CD28 T cell costimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol., 2009,104,276-284.
127. Merrill, J.T.; Merrill, J.T.; Burgos-Vargas, R.; Westhovens, R.; Chalmers, A.; D'Cruz, D.; Wallace, D.J.; Bae, S.C.; Sigal, L.; Becker, J.C. Kelly, S.; Raghupathi, K.; Li, T.; Peng, Y.; Kinaszczuk, M.; Nash, P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2010,62,3077-3087.
128. Robak, T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur. J. Haematol., 2004, .72, 79-88. (Pubitemid 38161156)
129. Cragg, M.S.; Walshe, C.A.; Ivanov, A.O.; Glennie, M.J.The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun., 2005;8;140-174.
130. Robak, T.; Robak, E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs, 2011,.25, 13-25.
131. Lim, S.H.; Beers, S.A.; French, R.R.; Johnson, P.W.; Glennie, M.J.; Cragg, M.S. Anti-CD20 monoclonal antibodies: Historical and future perspectives. Haematologica., 2010, 95, 135-143.
132. Lu, T.Y.; Ng, K.P.; Cambridge, G.; Leandro, M.J.; Edwards, J.C.; Ehrenstein, M.; Isenberg, D.A. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum., 2009, 61, 482-487.
133. Cambridge, G.; Isenberg, D.A.; Edwards, J.C.; Leandro, M.J.; Migone, T.S.; Teodorescu, M.; Stohl, W. B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis,. 2008, 67, 1011-1016. (Pubitemid 351956665)
134. Robak, E. ; Robak, T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr. Drug Targets, 2009, 10, 26-37.
135. Østergaard, M.; Baslund, B.; Rigby, W.; Rojkovich, B.; Jorgensen, C.; Dawes, P.T.; Wiell, C.; Wallace, D.J.; Tamer, S.C.; Kastberg, H.; Petersen, J.; Sierakowski, S. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum., 2010, 62, 2227-2238.
136. Goldenberg, D.M.; Rossi, E.A., Stein, R.; Cardillo, T.M.; Czuczman, M.S.; Hernandez-Ilizaliturri, F.J.; Hansen, H.J.; Chang, C.H. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti- CD20 monoclonal antibody. Blood, 2009, 113, 1062-1070.
137. Morschhauser, F.; Leonard, J.P.; Fayad, L.; , Coiffier, B.; Petillon, M.O.; Coleman, M.; Schuster, S.J.; Dyer, M.J.; Horne, H.; Teoh, N.; Wegener, W.A.; Goldenberg, D.M. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J. Clin. Oncol., 2009, 27, 3346-3353.
138. Kausar, F.; Mustafa, K.; Sweis, G.; Sawaqed, R.; Alawneh, K.;, Salloum, R.; Badaracco, M.; Niewold, T.B.; Sweiss, N.J. Ocrelizumab: A step forward in the evolution of B-cell therapy. Expert. Opin. Biol. Ther, 2009, 9, 889-895.
139. Genovese, M.C.; Kaine, J.L.; Lowenstein, M.B.; Del Giudice, J.; Baldassare, A.; Schechtman, J.; Fudman, E.; Kohen, M.; Gujrathi, S.; Trapp, R.G.; Sweiss, N.J.; Spaniolo, G.; Dummer, W.; ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum, 2008, 58, 2652-2661.
140. Faria, R.M. & Isenberg, DA. Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus. Lupus, 2010, 19, 1256-1257.
141. Czuczman, M.S., Gregory S.A. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk. Lymphoma., 2010, 51, 983-994.
142. Robak, T. GA-101, a third-generation, humanized and glyco-engineered anti- CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs, 2009, 10, 588-596.
143. Bologna, L.; Gotti, E.; Manganini, M.; Rambaldi, A.; Intermesoli, T.; Introna, M.; Golay, J. Mechanism of Action of Type II, Glycoengineered, Anti- CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab. J. Immunol., 2011, 186, 3762-3769.
144. Rubbert-Roth, A. TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis. Curr. Opin. Mol. Ther., 2010, 12, 115-123.
145. Robak, T.; Robak, P.; Smolewski, P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr. Opin. Investig. Drugs, 2009, 10, 1383-1390.
146. Hayden-Ledbetter, M.S.; Cerveny, C.G.; Espling, E.; Brady, W.A.; Grosmaire, L.S.; Tan, P.; Bader, R.; Slater, S.; Nilsson, C.A.; Barone, D.S.; Simon, A.; Bradley, C.; Thompson, P.A.; Wahl, A.F.; Ledbetter, J.A. CD20- directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin. Cancer Res., 2009, 15, 2739-2746.
147. Burge, D.J.; Bookbinder, S.A.; Kivitz, A.J.; Fleischmann, R.M.; Shu, C.; Bannink, J. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study. Clin. Ther, 2008, 30, 1806-1816.
148. King, J.K. ; Hahn, B.H. Systemic lupus erythematosus: Modern strategies for management: A moving target. Best Pract. Res. Clin. Rheumatol,. 2007, 21, 971-987. (Pubitemid 350194036)
149. Toubi, E.; Kessel, A.; Rosner, I.; Rozenbaum, M.; Paran, D.; Shoenfeld, Y. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand. J. Immunol., 2006, 63, 299-303
150. Wiglesworth, A.K.; Ennis, K.M. & Kockler, D.R. Belimumab: A BLySspecific inhibitor for systemic lupus erythematosus. Ann. Pharmacother., 2010, 44, 1955-1961.
151. Baker, K.P.; Edwards, B.M.; Main, S.H.; Choi, G.H.; Wager, R.E.;, Halpern, W.G.; Lappin, P.B.; Riccobene, T.; Abramian, D.; Sekut, L.; Sturm, B.; Poortman, C.; Minter, R.R.; Dobson, C.L.; Williams, E.; Carmen, S.; Smith, R.; Roschke, V.; Hilbert, D.M.; Vaughan, T.J.; Albert, V.R. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum., 2003, 48, 3253-3265. (Pubitemid 37409340)
152. Navarra, S.V.; Guzmán, R.M.; Gallacher, A.E.; Hall, S.; Levy, R.A.; Jimenez, R.E.; Li, E.K.; Thomas, M.; Kim, H.Y.; León, M.G.; Tanasescu, C.; Nasonov, E.; Lan, J.L.; Pineda, L.; Zhong, Z.J.; Freimuth, W.; Petri, M.A.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet, 2011, 377, 721-731.
153. Wu, Y.; Bressette, D.; Carrell, J.A.; Kaufman, T.; Feng, P.; Taylor, K.; Gan, Y.; Cho, Y.H.; Garcia, A.D.; Gollatz, E.; Dimke, D.; LaFleur, D.; Migone, T.S.; Nardelli, B.; Wei, P.; Ruben, S.M.; Ullrich, S.J.; Olsen, H.S.; Kanakaraj, P.; Moore, P.A.; Baker, K.P. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem.; 2000, 275, 35478-35485.
154. Pena-Rossi, C.; Nasonov, E.; Stanislav, M.; Yakusevich, V.; Ershova, O.; Lomareva, N.; Saunders, H.; Hill, J.; Nestorov, I. An exploratory doseescalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus, 2009,18,547-555.
155. Dall'Era, M.; Chakravarty, E.; Wallace, D.; Genovese, M.; Weisman, M.; Kavanaugh, A.; Kalunian, K.; Dhar, P.; Vincent, E.; Pena-Rossi, C.; Wofsy, D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus rythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum., 2007, 56,4142-4150. (Pubitemid 350262342)
156. Nestorov, I.; Papasouliotis, O.; Pena Rossi, C.; Munafo, A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci. 2010,99,524-538.
157. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther. 2008,10, 202.
158. Rönnblom, L.; Elkon, K.B. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol., 2010, 6, 339-347.
159. Aringer, M.; Feierl, E.; Steiner, G.; Stummvoll, G.H.; Höfler, E.; Steiner, C.W.; Radda, I.; Smole, J.S.; Graninger, W.B.Increased bioactive TNF in human systemic lupus erythematosus: Associations with cell death. Lupus, 2002,11,102-108. (Pubitemid 34259440)
160. Zhu, L.J.; Yang, X.; Yu, X.Q. Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:465898. Epub 2010 Jun 22.
161. Edwards, C.K 3rd.; Zhou, T.; Zhang, J.; Baker, T.J.; De M, Long, R.E.; Borcherding, D.R.; Bowlin, T.L.; Bluethmann, H.; Mountz, J.D. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α Journal of Immunology, 1996,157,1758-1772. (Pubitemid 126449121)
162. Klapman, J.B.; Ene-Stroescu, D.; Becker, M.A.; Hanauer, S.B. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis., 2003, 9, 176-178. (Pubitemid 36592448)
163. Smolen, J.S.; Emery, P. Infliximab: 12 years of experience. Arthritis Res Ther., 2011,13 Suppl 1, S2.
164. Uppal, S.S.; Hayat, S.J.; Raghupathy, R. Efficacy and safety of infliximab in active SLE: A pilot study. Lupus. ,2009,18,690-697A.
165. Aringer, M.; Houssiau, F.; Gordon, C.; Graninger, W.B.; Voll, R.E.; Rath, E.; Steiner, G.; Smolen, J.S. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: Long-term follow-up of 13 patients. Rheumatology, 2009,48,1451-1454.
166. Venegas-Pont, M.; Manigrasso, M.B.; Grifoni, S.C.; LaMarca, B.B.; Maric, C.; Racusen, L.C.; Glover, P.H.; Jones, A.V.; Drummond, H.A.; Ryan, M.J. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension, 2010 ,56, 643-649.
167. Shakoor, N.; Michalska, M.; Harris, C.A.; Block, J.A. Drug-induced systemic lupus eythematosus associated with etanercept therapy. Lancet, 2002,359,579-580. (Pubitemid 34178442)
168. Mor, A.; Bingham, C 3rd.; Barisoni, L.; Lydon, E.; Belmont, H.M. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol., 2005, 32, 740-743. (Pubitemid 40524710)
169. Robak, E.; Sysa-Jedrzejewska, A.; Dziankowska, B.; Torzecka, D.; Chojnowski, K.; Robak, T. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz)., 1998,46,375-380.
170. Nicoletti, F.; Di Marco, R.; Zaccone, P.; Xiang, M.; Magro, G.; Grasso, S.; Morrone, S.; Santoni, A.; Shoenfeld, Y.; Garotta, G.; Meroni, P. Dichotomic effects of IFN-a on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. Eur. J. Immunol., 2000,30,438-447. (Pubitemid 30098836)
171. Dong, L.; Ito, S-I.; Ishii, K.J.; Klinman, D.M. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis and Rheumatism., 2004,50,1686-1689. (Pubitemid 38608092)
172. Ronnblom, L.; Eloranta, M.L.; Alm, G.V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 2006,54,408-420. (Pubitemid 43228615)
173. Bengtsson, A.A.; Sturfelt, G.; Truedsson, L.; Blomberg, J.; Alm, G.; Vallin, H.; Rönnblom, L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus, 2000, 9, 664-671 (Pubitemid 32011791)
174. Merrill, J.T, Wallace, D.J.; Petri, M.; Kirou, K.A.; Yao, Y.; White, W.I.; Robbie, G.; Levin, R.; Berney, S.M.; Chindalore, V.; Olsen, N.; Richman, L.; Le, C.; Jallal, B.; White, B.; for the Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile, pharmacokinetics, immunogenicity, and clinical activity of sifalimumab, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Ann Rheum Dis., 2011, Jul 27. Epub ahead of print].
175. Gröndal, G.; Gunnarsson, I.; Rönnelid, J.; Rogberg, S.; Klareskog, L.; Lundberg, I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol., 2000,18,565-570.
176. Jones, G.; Ding, C. Tocilizumab: A review of its safety and efficacy in rheumatoid arthritis. Clin Med. Insights Arthritis Musculoskelet Disord., 2010, 19,81-89.
177. Liang, B.; Gardner, D.B.; Griswold, D.E. Bugelski, P.J.; Song, X.Y. Antiinterleukin- 6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology, 2006, 119, 296-305. (Pubitemid 44571047)
178. Illei, G.G; Shirota, Y.; Yarboro, C.H.; Daruwalla, J.; Tackey, E.; Takada, K.; Fleisher, T.; Balow, J.E.; Lipsky, P.E. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum., 2010, 62, 542-552.
179. Ratner, M. Human Genome Sciences trial data wow lupus community. Nat Biotechnol. 2009, 27, 779-780.
180. Xu, Z., Bouman-Thio, E., Comisar, C., Frederick, B., Van Hartingsveldt, B., Marini, J.C., Davis, H.M., Zhou, H. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011, 72, 270-281.
181. Parker, C.J.; Kar, S. & Kirkpatrick, P. Eculizumab. Nat. Rev. Drug Discov., 2007, 6, 515-625.